Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Actemra | Tocilizumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | ||
| Silkis | Calcitriol | Psoriasis, mild to moderate plaque | Do not list | Complete | ||
| Adcirca | Tadalafil | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete | ||
| Prezista | Darunavir | HIV infection (Pediatric) | List with clinical criteria and/or conditions | Complete | ||
| Jurnista | Hydromorphone hydrochloride | Pain, Chronic (moderate to severe) | Do not list | Complete | ||
| Isentress | Raltegravir | HIV (treatment naïve) | Do not list | Complete | ||
| Lotemax | Loteprednol etabonate | Post-operative inflammation following cataract surgery | Do not list | Complete | ||
| Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete |
Last Updated : May 14, 2024